Buradasınız

Anasayfa » Content

Differansiye tiroid kanserli hastalarda 1-131 taramalar ve TC-99M sestamibi tüm vücut taramaların karşılaştırılması

Comparison of TC-99M sestamibi with f-131 whole body seans in differentiated thyroid carcinoma patients

Journal Name:

  • Selçuk Tıp Dergisi

Publication Year:

  • 2004

Key Words:

Keywords (Original Language):

Author NameUniversity of Author
Abstract (2. Language): 
This study evafuated the potentiai of Tc-99m sestamibi vvhole body scan as an alternative to vvhole body I-131 scan for well differentiated thyroid cancer patients prior to 1-131 ablation and post abiation states. We evaiuated 115 patients vvith differentiated thyroid cancer who had total or near total thyroidectomy. Ali patients had undergone Tc-99m sestamibi whole body scanning. high resolution neck uttrasonography prior to conventional 1-131 vvhole body scanning, thyrogiobulin, and antithyroglobulin values measured. Also ali patients had neck and ehest CT vvıthout contrast agent The results shovved that Tc-99m sestamibi vvhole body images are highly sensitive and specific in dif¬ferentiated thyroid carcinoma patients vvithout thyroid supression ff4-offj, compared to conventional 1-31 vvhole body seans (kappa=0.68 p<0.00 Ij. Neck USG vvith Tc-99m sestamibi İs comparable vvith conventional iodine based vvhole body studies also compared to high dose post -ablation 6th day I-131 vvhole body seans. Neck USG inereases sen-sitivity and decreases specifîcity of Tc-99m sestamibi seans. Clinical investigations had to be made to evaluate the effı-cieney of Tc-99m sestamibi in patients receiving thyroid supression.
Bookmark/Search this post with
Abstract (Original Language): 
Bu çalışma ablasyon öncesi ve sonrasında iyi differansiye tiroid kanserli hastalarda alternatif tarama yöntemi olarak Tc-99m sestamib/'nin kullanılıp kullanılamayacağını değerlendirmiştir. Bu nedenle total veya totale yakın tiroidektomı uygulanan 115 differansiye tiroid kanseri hastası çalışmaya alindi- Tüm hastalara Tc-99m sestamibi tüm vücut tarama, yüksek rezoiüsyoniu boyun USG. serum tiroglobulin ve antitiroglobuiin ölçümleri ve kontrastsız boyun ve toraks tomo¬grafileri yapıldı. Sonuçlar göstermiştir ki Tc-99m Sestamibi tüm vücut taramalar, 1-131 taramalarla karşılaştırıldığında tiroid supresyonu almayan (T4off) hastalarda yüksek derecede sensitif ve spesifiktir jkappa -0.68 ÇKO.001). Boyun USG ile birlikte Tc-99m sestamibi yapılması, yüksek doz 1-131 ablasyonu sonrası 6. gün taramalarla karşılaştırılabilir etkinliğe sahiptir. Boyun USG, Tc-99m Sestamibi'nin sensitivitesini arttırırken spesifısitesini azaltır. Ancak Tc-99m Sestamibinin tiroid supresyonu alan hastalarda etkinliğinin değerlendirilmesi için klinik çalışmalara ihtiyaç vardır.
FULL TEXT (PDF): 
PDF icon arastirmax-differansiye-tiroid-kanserli-hastalarda-1-131-taramalar-tc-99m-sestamibi-tum-vucut-taramalarin-karsilastirilmasi.pdf
  • 4
128-134
  • Turkish

REFERENCES

References: 

Maxon HR, Smith HS. Radioiodine-131 in the diagnosis and treatment of metastatic vvell-differentiated thyroid cancer. Endocrinol Metab Cin North Am 1990; 19:685¬718
2. Meier CA. Braverman LE, Ebner SA, Veronikis I. Daniel GH, Ross DS. et al. Diagnostic use of recombinant human thyrotropin in patients vvith thyroid carcinoma jghase l/ll study). J Clin Endocrinol Metab 1994; 78:188¬
3. Miyamoto S, Kasagai K.Mİsaki T, Alam MS, Konishi J. Evaluation of tecnnetium-99m-MIBI scintigraphy in metastatic differentiated thyroid carcinoma. J Nucl Med 1997; 38:352-6

4. Oyen WJ, Verhagen C. Saris E. van den Broek Wj, Pıeters GF, Corsten FH. Follow-up regimen of differentiated thy¬roid carcinoma in thyroıdecromized patients after thyroid hormone vvithdravval. J Nucl Med 2000; 41:643-6
5. Pacini F,Üppi F, Formica N, Elisei R, Anelli S, Ceccarelii C. et al. Therapeutıc doses of iodine-131 reveal undiag-nosed metastases in thyroid cancer vvith detectable serum thyroglobulin levels. J Nucl Med 1987; 28:1888¬91
6. Mc Dougall İR :72 MBg radioiodine 131-1 does not pre-vent uptake of therapeutic doses of 131-1 [i.e. it does not cause stunning) in differentiated thyroid cancer.Nucl Med Commun 1997; 18:505-12

7 Muratet JP. Daver A. M/nrer JF. Larra F. et al influence of scanning üoses of jodme - 131 on subsequent fırst abiatıve treatment ouicome ın patients operated on for differentiated thyroid carcinoma J Nucl Med 1998. 39. 1546-50
8 Muratet JP, Gıraud P. Daver A. MınıerJF. GamelınE. Larra F. et al. Predrctıng the effıcacy of first 1-131 treatment ın differentiated thyroid carcinoma, J Nucl Med 1997; 38:1362-8
9 Park HM. Park Yh, Zhou XH. Detection of thyroid rem-nant /metastasıs vvıthout stunning An ongoıng dilem¬ma. Thyroid 1997; 7:277-80

10. Cholevvınsky SP. Yoo KS. Klıeger PS. O'Mara RE Aosence of thyroid scanning after diagnostic whole-body scan¬ning vvith 185 MBq I-I3I. J Nucl Med 2000; 41:1 198¬202
11. Maxon HR. Smıth HS Radioiodine-131 ın the diagnosis and treatment of metastatic ıvell-dıfferentıated thyroid cancer Endocrinol Metab Cim North Am 1990. 19:685¬718
12. Kasagı K, Miyamoto S. Endo K, Saoayama S. Takeuchi R. Hıdaka A et al. Increased uptake of lodine-131 in metas¬tases of differentiated thyroid carcinoma assocıated wıth less severe hypothyroıdism follovvıng total thyroıdecto-my. Cancer 1993; 72:1983-90
13. Khammash N.Halkar R,Abdel-Dayem HM The use of Tc-99m pertechnetate ın postoperatıve thyroid carcinoma A comparatrve study wıth lodine-13 Cim Nucl Med 1988. 13:17-22
14 ün JD.Kao PF, VVeng HF, Lu WT, Huang MJ. Relatıve vaiueof thallıum-20i and iodıne-131 seans in the detec¬tion of recurrence or dıstant metastases of vvell-differenti¬ated thyroid carcinoma, Eur J Nucl Med 1998; 25:695¬700
15. Lind P. Gallovvıtsch Hj. Langsteger W. Kresnık E. Mıkosch P. Gomez I Tecnetıum-99m-tetrofosmin vvhole-body scintigraphy ın the follow-up of differentiated thyroid car¬cinoma. J. Nucl Med 1997; 38:348-52
16 Maxon HR. Smıth HS Radıoıodıne-131 ın the diagnosis and treatment of metastatic vvelFdıfferentıated thyroid cancer Endocrinol Metab Clın North Am 1990 19.635¬718
17. Miyamoto S. Kasagai K.Misakı T. Alam MS. Konishi J Evaluation of technetıum-99m-MIBI scintigraphy in metastatic differenoated thyroid carcinoma J Nucl Med 1997; 38.352-6
18. Mueller S, Piotrovvskı 8. Guth-Tougelıdes B Technetıurrv 99m-MIB! and Tf-201 uptake ın thyroid carcinoma J Nucl Med 1989; 30:38-44

19 Nakahara H.Noguchı S. Murakamı N, Hoshı H. Jınnouchı S. Nagamachı S Technetıum-99m sestamibi scintigraphy compared wıth thallıum-201 ın evaluation of thyroid tumors J Nucl Med 1996; 37:901-4
20 Nemec J. Nyvltova O.Blazek T, Vıcek P, Racek P. Novak Z Posıtive thyroid cancer scıntıgrapy usıng technetium-99m methoxyısobutylnıtrıle Eur J Nucl Med 1996. 23:69-71
21 Ng D.Sundram F.Sın A 99mTc-5estamıbı and 131 I
vvhole-body scintigraphy and ınmal serum thyroglobulın
m the management of differentiated thyroid carcinoma
J Nucl Med 2000. 41: 631-5
22. Oyen WJG. Verhagen C. Sarış E. van den Broek WJ. Pıeters GF. Corsten FH Follovv-up regımen of differenti¬ated thyroid carcinoma ın thyroıdectomızed patients after thyroid hormone vvithdravval J Nucl Med 2000; 4 I 643¬6
23. Pacıni F.üppı F, Formica N. Ellıseı R. Anellıs S, Ceccarellı C, et al. Therapeutic dose of ıodıne-131 reveal undıag-nosed metastases ın thyroid cancer vvith deteetable serum thyroglobulın levels J Nucl Med 1987; 28:1888¬91
24. Pıneda JD, Lee T. Aın K, Reynolds JC. Robbıns J lodıne-131 therapy for thyroid cancer patients vvith elevated thy¬roglobulın and negatıve diagnostic scan. J Clın Endocrinol Metab 1995; 80:1848-92

25 Pıttas AG, Adler M.Fazzarı M. Tıckoo S. Rosaı J. Larson SM. et al. Bone metastases from thyroid carcinoma: Clınıcal characterıstıcs and prognostıc vanables ın one hundred forty-six patients Thyroid 2000; 10:261-8
26 Franceschı M. Kusıc Z. Franceshı D. Lukınac L, and Roncevıc S Thyroglobulın Determınatıon. Neck Ultrasonograpy and lodine-131 Whole-Body Scintigraphy ın Differentiated Thyroid Carcinoma. J Nucl Med. 1996; 37; 446-51
27 Lınd Pl vvhole body scıntıgraphye ın thyroid cancer patients OJ Nucl Med 1999. 188-94
28. Morris LF Waxman AD. and Braunsteın GD The Nonımpact of Thyroid Stunning: Remnant Ablation Rates in 131-1 Scanned and Nonscanned Indıviduals. J Clin Endocnnal Metab 2001; 86 : 3507-1 I
29 Lorberboym M.Murthy S. Mechanick Jl, Bergman D, Morris JC. Kim CK. Serum thyrogbulın and iodine-131 scintigraphy ın differentiated thyroid carcinoma J Nucl Med 1996. 37.1487-91

Thank you for copying data from http://www.arastirmax.com